Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
moving $6.50 name change: HROW
super buy if it gets hit by the overall market down at $4.10-$4.25. A $10 stock by 2020 at a minimum.
IMMY - New Analyst Coverage with $10 target. Confident about operating cash flow, cancelled ATM with Cantor Fitz. Increased institutional interest. YoY revenue growth pretty impressive. Doing about ~$40MM/yr currently, with PPS at ~$5.50 market cap is ~$125MM. Compared to most of the other junk out there, this company is pretty undervalued right now, and growing rather quickly. Worth taking a look!
IMMY i did sell...the PPS too ahead of the top bands!!
Yeah---adding to more companies to the IPO/spinoff list is fuel for the fire---reminds me of Safeguard Scientific during the internet boom!
IMMY the monster is mad and she is running fast!!
IMMY nice friday runner!!!
IMMY///find the good ones and hold!! With the big boards...patience is key!!!
Market capitalization = # common shares outstanding x price per share, and is the fair value “investors” deem the company to be worth. I don’t believe that by having a % ownership in another company, the market cap changes in relation to an IPO. Neither the # outstanding shares nor the PPS changes. (Well, technically the PPS changes if investor sentiment is positive or negative regarding ownership of IPO company.) My question is less about “market valuation” and more about actual reporting data (i.e. balance sheet, income statement, cash flow statement, and statement of changes in stockholder equity). In other words, how would the potential IPO of ETON affect IMMY’s reported financials, if at all?
I believe in most simple terms it comes down to market cap value. If company A with market cap value of $50M owns 30% of company B with market cap of $100M. Then add $30M in market cap to company A. So fair value of company A becomes more solidly valued at $80M at the time it (company B) goes public.
I’m sure I’m oversimplifying and some value of ETON is already baked into the IMMY stock price before its IPO but ...
IMMY value will directly relate to how ETON IPOs and its value after. At the moment I don’t believe we know the IPO stock price of ETON nor (more importantly) how it will perform in the open market.
Question:
Admittedly, I have no experience or understanding of the effects of a company having a % owndership in another company that IPOs. How does the increase in cash and equity on the IPO company’s balance sheet affect the owner’s balance sheet and income statement (in accounting terms please)?
Thank you in advance.
Another good day. I should have bought more.
Good find and thank you.
MELT presentation:
http://secfilings.com/searchresultswide.aspx?link=2&filingid=13026047
Bought in at 3.32 and so far been happy with the direction it's heading. Good luck to all.
Eton is pricing tomrw if all goes well. The underwriter leaves a lot to be desired but it sure beats no IPO.
Another item is the presentation of Melt in Chicago this weekend. Melt could be huge.
https://globenewswire.com/news-release/2018/10/16/1621771/0/en/ImprimisRx-to-feature-new-formulation-and-poster-presentation-on-MKO-Melt-at-the-upcoming-American-Academy-of-Ophthalmology-Meeting-in-Chicago.html
I must admit, I was excited listening to the Q2 Earnings call, but at the same time the analyst in me reminded myself that it’s the CEO and CFO’s job to inspire and excite investors. It’s our job as investors to remain objective and stick to sound DD. That said, my current thoughts:
With regard to the short term stock price valuation of the company, we have to ask ourselves, what is the next catalyst that’s going to drive the price up or down? My guess would be Q3 Earnings in November. So what can we expect? My guess would be increased sales figures for the optics business, improving top line results. My second guess would be losses on the bottom line due to no gain from ‘deconsolidation’ as was the case in Q217 and Q218, which created short term positive EPS. I’m also interested in seeing how many new shares were sold.
I think longer term, the company is well positioned to grow. The next catalyst that may drive buying is the IPO. Does anyone know when this is expected to happen?
Key takeaways Q2 CC CEO Mark "it's an exciting time""fantastic Q congratulations""turning the corner""move to $100M rev run rate""we are at 60% margins and grow to 70%""leading Opthomology co. in US""100% commission sales force (100 people) doubled"
They’re moving in the right direction. Add ETON and others and it all propels IMMYs bottom line.
Will be listening to Q3 CC closely.
balance sheet is very good here...pretty low market cap!!
Technically, yes you are right the company did report positive EPS (.11 diluted) in Q218. I was implying the company still isn't profitable from regular operations (sales revenue-cost to produce-cost to sell and maintain day to day operations), not including 'other income', which isn't recurring or part of normal business. Gains from the deconsolidation of the subsidiaries (Eton and, specifically Surface) recorded in other income are what boosted net income to positive in Q217 and Q218. A sustainable businesses strategy isn't to be an incubation machine for subsidiary spin-offs. In order to grow and become profitable, the company will have to increase sales and improve operating efficiency. I'm just wondering what the plan is to accomplish this?
Not true. Company WAS PROFITABLE last Q. Don’t forget value of ETON is $20M+ add to market cap alone once IPO closes. Don’t forget value of Melt which had its own progress announcement this week. Margins are also expected to improve this quarter per CEO comments. Revenue growth y/oY was 85%.
Re-listen to last Q2 conference call. Tremendously good things happening in this small cap stock.
Stay tuned for more.
IMMY What do you think is driving this accumulation? At today's close, the market is now valuing the company at ~$90MM. Sales revenue has been ramping up at about 70% YOY as of 6/30/18, and the company will probably report annual sales revenue of ~$40MM. Still, not yet profitable as there are losses from operations in each quarter. Income from deconsolidation of subsidiaries is the only thing somewhat improving the bottom line. What is the company's strategy to become profitable?
big board bio buy today....IMMY watch this bio beast run!!!
Record numbers and potentially IPOing three companies of which they will own a third.
Read up on Melt---potential game changer here---will be discussed this coming weekend at the Ophthalmology Conference in Chicago.
Just came across this stock. Look's like it may have some possibilities.
Did You Not Hear Me? This Mother Come Monday Is Going to Blow The Fu*k Up!! Sorry Shorts.... HeHeHe,,
* * $IMMY Video Chart 01-30-18 * *
Link to Video - click here to watch the technical chart video
jumped in on the pullback to $1.94
fingers crossed
$IMMY
Apparently IMMY is owned by fitbit. Whoda thunk?
http://www.journalfinance.net/2017/10/oscillating-stock-imprimis-pharmaceuticals-inc-nasdaqimmy-fitbit-inc-nysefit-therapeuticsmd-inc-nasdaqtxmd/
* * $IMMY Video Chart 10-19-17 * *
Link to Video - click here to watch the technical chart video
huge buying opportunity on this minor dip:
October 19, 2017
4:51 pm ET
*Imprimis CEO Mark Baum Tells Benzinga Co. Will Not Compound A Copy Of Restais As It Is Illegal, Will Use Patent-Pending Topical Cyclosporine Formulation To Compound Drug To The Individual Patient's Need From A Physician's Prescription
Benzinga
*Imprimis CEO Mark Baum Tells Benzinga Co. Will Not Compound A Copy Of Restais As It Is Illegal, Will Use Patent-Pending Topical Cyclosporine Formulation To Compound Drug To The Individual Patient's Need From A Physician's Prescription
Benzinga
Shares of Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) got a boost, shooting up 63 percent to $2.38 after the company announced Thursday the release of a 99-cent alternative to Allergan PLC (NYSE: AGN)'s Restasis to address the 30 million Americans suffering from Dry Eye Disease.
high for the day is $2.79.
it may hit $3 today.
Longboard Capital Advisors, LLC has filed a new 13G, reporting 6.58% ownership in $IMMY - https://fintel.io/so/us/immy
Looks a lot like IMMY
True Nature Expands Board, Appoints Senior Pharma Executive http://finance.yahoo.com/news/true-nature-expands-board-appoints-140000192.html
Any idea what these guys are doing now?
Back in at 3.81
That Martin clown that jacked price on the drug got arrested today and his company's stock halted
He just doesn't get it. Karma is gonna hurt someday.
“I probably would have raised prices higher, is probably what I should have done. I could have raised it higher and made more profits for our shareholders. Which is my primary duty.”
http://www.stardailystandard.com/business/martin-shkreli-i-ought-tove-raised-costs-greater/34838/
Hey SG..
I guess the easiest way to answer that is referring to another post answering a concern about their split history:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=118466368
In 2011 Transdel filed for a petition for reorganization under chapter 11 in Bankruptcy court. This timeline coincides with when Mark Baum was brought on as CEO; also 2011. Baum saw the company through the restructuring that year and they requested the court to dismiss the chapter 11 in November 2011. In Feb 2012, they changed their name to Imprimis.
I believe the company than seized the opportunity of compounding pharma on the passing of the Drug Quality and Security Act of 2013 which was put in place to employ strict guidance and oversight in the compounding pharmacy industry.
Not sure if you've read it but here's a link:
http://www.fda.gov/drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding/
So Imprimis used to be transdel pharmaceuticals...
Was this an OTC stock? Any information you know I would appreciate
https://www.lawinsider.com/contracts/4sDJVu6vj3XqN5DC7BZavb/transdel-pharmaceuticals/agreement/2015-02-02
Followers
|
59
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3167
|
Created
|
07/01/11
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |